Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Steroid Therapy in Autoimmune Premature Ovarian Failure
Autoimmune Premature Ovarian Failure: A Controlled Trial of Alternate-Day Prednisone Therapy
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Steroid Therapy in Autoimmune Premature Ovarian Failure
Autoimmune Premature Ovarian Failure: A Controlled Trial of Alternate-Day Prednisone Therapy
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Central Arkansas Veterans Healthcare System
mi
from
Little Rock, AR
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Updated: 1/1/1970
Central Arkansas Veterans Healthcare System
mi
from
Little Rock, AR
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
LA County/USC Medical Center
mi
from
Los Angeles, CA
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Updated: 1/1/1970
LA County/USC Medical Center
mi
from
Los Angeles, CA
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Unversity of California, San Francisco
mi
from
San Francisco, CA
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
mi
from
San Francisco, CA
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Denver Health and Hospital Authority
mi
from
Denver, CO
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Updated: 1/1/1970
Denver Health and Hospital Authority
mi
from
Denver, CO
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Emory Umiversity School of Medicine
mi
from
Atlanta, GA
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Updated: 1/1/1970
Emory Umiversity School of Medicine
mi
from
Atlanta, GA
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Chicago-Lakeside VAMC
mi
from
Chicago, IL
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Updated: 1/1/1970
Chicago-Lakeside VAMC
mi
from
Chicago, IL
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Harlem Hospital, Columbia University
mi
from
New York, NY
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Updated: 1/1/1970
Harlem Hospital, Columbia University
mi
from
New York, NY
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
University of North Texas Health Science Center
mi
from
Fort Worth, TX
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Updated: 1/1/1970
University of North Texas Health Science Center
mi
from
Fort Worth, TX
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Audie L Murphy Veterans Administration Hospital
mi
from
San Antonio, TX
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Updated: 1/1/1970
Audie L Murphy Veterans Administration Hospital
mi
from
San Antonio, TX
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Seattle King County Health Department
mi
from
Seattle, WA
TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment
Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB
Status: Archived
Updated: 1/1/1970
Seattle King County Health Department
mi
from
Seattle, WA
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
Status: Archived
Clinical Alliance for Research and Education - Infectious Diseases, LLC
mi
from
Annandale, VA
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
Status: Archived
Updated: 1/1/1970
Clinical Alliance for Research and Education - Infectious Diseases, LLC
mi
from
Annandale, VA
Drug Interaction Study Between Antimalarial and Anti-HIV Medications
Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combination, Artemether/Lumefantrine
Status: Archived
San Francisco General Hospital
mi
from
San Francisco, CA
Drug Interaction Study Between Antimalarial and Anti-HIV Medications
Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combination, Artemether/Lumefantrine
Status: Archived
Updated: 1/1/1970
San Francisco General Hospital
mi
from
San Francisco, CA
STD Risk Reduction for Heterosexual Methamphetamine Users
Reducing HIV/STD Risk, Methamphetamine Use, and Depression Among Heterosexuals
Status: Archived
HIV Neurobehavioral Research Center
mi
from
San Diego, CA
STD Risk Reduction for Heterosexual Methamphetamine Users
Reducing HIV/STD Risk, Methamphetamine Use, and Depression Among Heterosexuals
Status: Archived
Updated: 1/1/1970
HIV Neurobehavioral Research Center
mi
from
San Diego, CA
Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo
Placebo-Controlled Study of Pregabalin for the Pain of Acute Herpes Zoster
Status: Archived
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo
Placebo-Controlled Study of Pregabalin for the Pain of Acute Herpes Zoster
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults
A Phase 1 Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Chimeric Bovine/Human Parainfluenza Type 3 Virus Vaccine, rB/HPIV3, Lot PIV3 #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV3-Seropositive Children 15 to 59 Months of Age, and HPIV3-Seronegative Infants and Children 6 to 36 Months of Age
Status: Archived
Center for Immunization Research
mi
from
Baltimore, MD
Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults
A Phase 1 Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Chimeric Bovine/Human Parainfluenza Type 3 Virus Vaccine, rB/HPIV3, Lot PIV3 #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV3-Seropositive Children 15 to 59 Months of Age, and HPIV3-Seronegative Infants and Children 6 to 36 Months of Age
Status: Archived
Updated: 1/1/1970
Center for Immunization Research
mi
from
Baltimore, MD
BCG Vaccination Delivered Intradermally, Orally and by Combined Routes
Phase I Studies of the Safety and Immunogenicity of Primary and Secondary BCG Vaccination Delivered Intradermally, Orally and by Combined Routes of Administration in Healthy and Previously Immunologically Naïve Volunteers
Status: Archived
St Louis University
mi
from
St Louis, MO
BCG Vaccination Delivered Intradermally, Orally and by Combined Routes
Phase I Studies of the Safety and Immunogenicity of Primary and Secondary BCG Vaccination Delivered Intradermally, Orally and by Combined Routes of Administration in Healthy and Previously Immunologically Naïve Volunteers
Status: Archived
Updated: 1/1/1970
St Louis University
mi
from
St Louis, MO
Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)
Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)
Status: Archived
Children's Medical Center of Dallas
mi
from
Dallas, TX
Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)
Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)
Status: Archived
Updated: 1/1/1970
Children's Medical Center of Dallas
mi
from
Dallas, TX
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Alabaster, AL
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Alabaster, AL
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Boise, ID
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Boise, ID
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Avon, IN
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Avon, IN
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Arkansas City, KA
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Arkansas City, KA
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Ashland, KY
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Ashland, KY
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Asheville, NC
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Asheville, NC
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Akron, OH
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Akron, OH
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Fletcher Allen Health Care
mi
from
Burlington, VT
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
mi
from
Burlington, VT
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Cranston, RI
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Cranston, RI
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Bristol, TN
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Bristol, TN
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
West Jordan, UT
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
West Jordan, UT
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Pfizer Investigational Site
mi
from
Seattle, WA
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Seattle, WA
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
Phase II, Multi-Center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis
Status: Archived
Children's Investigational Research Program, LLC (CHIRP)
mi
from
Bentonville, AR
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
Phase II, Multi-Center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis
Status: Archived
Updated: 1/1/1970
Children's Investigational Research Program, LLC (CHIRP)
mi
from
Bentonville, AR
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
Phase II, Multi-Center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis
Status: Archived
Harvey Pediatrics, PLLC
mi
from
Jonesboro, AR
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
Phase II, Multi-Center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis
Status: Archived
Updated: 1/1/1970
Harvey Pediatrics, PLLC
mi
from
Jonesboro, AR
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
Status: Archived
Staten Island University Hospital
mi
from
Staten Island, NY
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
Status: Archived
Updated: 1/1/1970
Staten Island University Hospital
mi
from
Staten Island, NY
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation
Status: Archived
Children's Hospital Central California
mi
from
Madera, CA
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation
Status: Archived
Updated: 1/1/1970
Children's Hospital Central California
mi
from
Madera, CA
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation
Status: Archived
UCSF Children's Hospital
mi
from
San Francisco, CA
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation
Status: Archived
Updated: 1/1/1970
UCSF Children's Hospital
mi
from
San Francisco, CA
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation
Status: Archived
Children's Medical Center of Dallas
mi
from
Dallas, TX
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation
Status: Archived
Updated: 1/1/1970
Children's Medical Center of Dallas
mi
from
Dallas, TX
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation
Status: Archived
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation
Status: Archived
Updated: 1/1/1970
Children's Hospital and Regional Medical Center - Seattle
mi
from
Seattle, WA
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Status: Archived
Washington University
mi
from
St. Louis, MO
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
Mycobacterium Avium Intracellulare Complex (MAC) Study
Pilot Study to Assess Safety and Efficacy of Short Course Multiple Drug Therapy for Adult Patients With Mycobacterium Avium Intracellulare Complex (MAC) Infection Associated With Mulit Focal Bronchiectasis and Multiple Small Nodules
Status: Archived
Mayo Clinic - Division of Nephrology
mi
from
Rochester, MN
Mycobacterium Avium Intracellulare Complex (MAC) Study
Pilot Study to Assess Safety and Efficacy of Short Course Multiple Drug Therapy for Adult Patients With Mycobacterium Avium Intracellulare Complex (MAC) Infection Associated With Mulit Focal Bronchiectasis and Multiple Small Nodules
Status: Archived
Updated: 1/1/1970
Mayo Clinic - Division of Nephrology
mi
from
Rochester, MN
Computer-Assisted Provision of Reproductive Health Care
Computer-Assisted Provision of Reproductive Health Care
Status: Archived
Unversity of California, San Francisco
mi
from
San Francisco, CA
Computer-Assisted Provision of Reproductive Health Care
Computer-Assisted Provision of Reproductive Health Care
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
mi
from
San Francisco, CA
Computer-Assisted Provision of Reproductive Health Care
Computer-Assisted Provision of Reproductive Health Care
Status: Archived
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Computer-Assisted Provision of Reproductive Health Care
Computer-Assisted Provision of Reproductive Health Care
Status: Archived
Updated: 1/1/1970
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults
A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31‐7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3
Status: Archived
Center for Immunization Research
mi
from
Baltimore, MD
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults
A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31‐7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3
Status: Archived
Updated: 1/1/1970
Center for Immunization Research
mi
from
Baltimore, MD
Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients
Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial
Status: Archived
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients
Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients
Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial
Status: Archived
University of Miami Hospital
mi
from
Miami, FL
Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients
Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
mi
from
Miami, FL
Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients
Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients
Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI